Advertisement

Does Prostaglandin Release Contribute to the Hypotension Induced by Inhibitors of Angiotensin Converting Enzyme?

  • Kevin Mullane
  • Salvador Moncada
  • John R. Vane

Abstract

The concept that angiotensin converting enzyme inhibitors might be useful therapeutic agents in the treatment of hypertension became a practical proposition in the mid-1960s as a result of the collaborative efforts of workers from quite different fields. In Brazil, Ferreira and co-workers1,2 had shown that metal chelating agents inhibited the inactivation of bradykinin by blood. Some thiol compounds such as BAL also potentiated the actions of bradykinin in vitro and in vivo.1 At that time it was known that the venom of the Brazilian snake Bothrops jararaca induced contraction of the isolated ileum of the guinea pig. While studying this effect, Ferreira et al. noticed that the venom itself strongly potentiated the effects of bradykinin.3 The authors then showed that the venom contained a peptide factor which was responsible for the potentiation and called this “bradykinin potentiating factor” or BPF.4 They also showed that this peptidic extract potentiated both the contractions induced by bradykinin on the guinea pig ileum in vitro and the hypotensive effect of the kinin in the cat and dog in vivo. This potentiation was later correlated with inhibition of kinin-inactivating enzymes.5,6

Keywords

Angiotensin Converting Enzyme Inhibitor Converting Enzyme Plasma Renin Activity Hypotensive Effect Prostaglandin Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ferreira SH, Rocha e Silva M: Potentiation of bradykinin by dimercaptopropanol (BAL) and other inhibitors of its destroying enzyme in plasma. Biochem Pharmacol 11: 1123, 1962.PubMedCrossRefGoogle Scholar
  2. 2.
    Ferreira SH, Corrado AP, Rocha e Silva M: Potenciacao do efeito lipotensor da bradicinina por inibicao da enzima bradicinonolitica plasmatica, Cienc Cult Sao Paolo 14: 238, 1962.Google Scholar
  3. 3.
    Ferreira SH, Rocha e Silva M: Poteniacao de polipeptideos por um fator presente no veneno de B. Jararaca. Cienc Cult Sao Paolo 15: 276, 1963.Google Scholar
  4. 4.
    Ferreira SH: A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Br J Pharmacol 24: 163, 1965.Google Scholar
  5. 5.
    Ferreira SH, Rocha e Silva M: Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca. Experentia 21: 347, 1965.CrossRefGoogle Scholar
  6. 6.
    Ferreira SH: Bradykinin potentiating factor, in Erdos G, Back N, Sicuteri F (eds): Hypotensive Peptides. New York, Springer Verlag, 1966, p 356.CrossRefGoogle Scholar
  7. 7.
    Ferreira SH, Vane JR: The detection and estimation of bradykinin in the circulating blood. Br J Pharmacol Chemother 29: 367, 1967.PubMedGoogle Scholar
  8. 8.
    Ferreira SH, Vane JR: The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br J Pharmacol Chemother 30: 417, 1967.PubMedGoogle Scholar
  9. 9.
    Ng KKF, Vane Jr: Conversion of angiotensin Ito angiotensin II. Nature 216: 762, 1967.PubMedCrossRefGoogle Scholar
  10. 10.
    Ng KKF, Vane JR: Fate of angiotensin I in the circulation. Nature 218: 144, 1968.PubMedCrossRefGoogle Scholar
  11. 11.
    Bakhle YS: Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 220: 919, 1968.PubMedCrossRefGoogle Scholar
  12. 12.
    Cushman DW, Cheung HS: Spectrophotometric assay and properties of the angtiotensin converting enzyme of rabbit lung. Biochem Pharmacol 20: 1637, 1971.CrossRefGoogle Scholar
  13. 13.
    Yang HYT, Erdos EG, Levin Y: Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). J Pharmacol Exp Ther 177: 291, 1971.PubMedGoogle Scholar
  14. 14.
    Igic R, Erdos EG, Yeh HSJ, et al: The angiotensin I converting enzyme of the lung. Circ Res 31 (Suppl. II): 22–51, 1972.Google Scholar
  15. 15.
    Ferreira SH, Bartelt DC, Greene LJ: Isolation of bradykinin potentiating peptides from Bothrops jararaca venom. Biochemistry 9: 25–83, 1970.CrossRefGoogle Scholar
  16. 16.
    Kreiger EM, Salgado HC, Assan CJ, et al: Potential screening test for detection of overactivity of renin-angiotensin system. Lancet 1: 269, 1971.CrossRefGoogle Scholar
  17. 17.
    Ondetti MA, Williams NJ, Sabo EF, et al: Angiotensin converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure and synthesis. Biochemistry 10: 4033, 1971.PubMedCrossRefGoogle Scholar
  18. 18.
    Collier JG, Robinson BF, Vane JR: Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (BPP9a or SQ20, 881) which inhibits converting enzyme. Lancet 1: 72, 1973.PubMedCrossRefGoogle Scholar
  19. 19.
    Case DB, Wallace JM, Keim HJ, et al: Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Am J Med 61: 790, 1976.PubMedCrossRefGoogle Scholar
  20. 20.
    Byers LD, Wolfenden R: Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A. Biochemistry 12: 2070, 1973.PubMedCrossRefGoogle Scholar
  21. 21.
    Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: A new class of orally active antihypertensive agents. Science 196: 441, 1977.PubMedCrossRefGoogle Scholar
  22. 22.
    Mita I, Iwao J, Oya M, et al: New sulfhydryl compounds with potent antihypertensive activities. Chem Pharm Bull Tokyo 26: 1333, 1978.PubMedCrossRefGoogle Scholar
  23. 23.
    Cushman DW, Ondetti MA: Inhibitors of angiotensin-converting enzyme, in Ellis GP, West GP (eds): Progress in Medicinal Chemistry. Elsevier/North Holland and Biomedical Press, 1980, p. 41.Google Scholar
  24. 24.
    Patchett AA, Harris E, Tristram EW, et al: A new class of angiotensin-converting enzyme inhibitors. Nature 288: 280, 1980.PubMedCrossRefGoogle Scholar
  25. 25.
    Editorial: Inhibitors of angiotensin I converting enzyme for treating hypertension. Br Med J 281: 630, 1980.CrossRefGoogle Scholar
  26. 26.
    Atkinson AB, Robertson JIS: Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 2: 836, 1979.PubMedCrossRefGoogle Scholar
  27. 27.
    Thurston H, Swales JD: Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor. Circ Res 42: 588, 1978.PubMedGoogle Scholar
  28. 28.
    Fagard RH, Amery AK, Lijnen PJ, et al: Comparative study of an angiotensin II analog and a converting enzyme inhibitor. Kidney Int 17: 647, 1980.PubMedCrossRefGoogle Scholar
  29. 29.
    Fouad FM, Ceimo JMK, Tarazi RC, et al: Contrasts and similarities of acute haemodynamic responses to specific antagonism of angiotensin II (Sar, Thr-AII) and to inhibition of converting enzyme (Captopril). Circulation 61: 163, 1980.PubMedGoogle Scholar
  30. 30.
    Regoli D, Park WK, Rioux F: II. Pharmacology of angiotensin antagonists. Can J Physiol Pharmacol 51: 114, 1973.PubMedCrossRefGoogle Scholar
  31. 31.
    Sen S, Smeby RR, Bumpus FM, et al: Role of renin—angiotensin system in chronic renal hypertensive rats. Hypertension 1: 427, 1979.PubMedGoogle Scholar
  32. 32.
    Marks ES, Bing RF, Thurston H, et al: Vasodepressor property of the converting enzyme inhibitor captopril (SQ14225): The role of factors other than renin—angiotensin blockade in the rat. Clin Sci 58: 1, 1980.PubMedGoogle Scholar
  33. 33.
    Gavras H, Brunner HR, Turini GA, et al: Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ14225 in man. N Engl J Med 298: 991, 1978.CrossRefGoogle Scholar
  34. 34.
    Bravo EL, Tarazi RC: Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1: 39, 1979.Google Scholar
  35. 35.
    Abe K, Itoh T, Imai Y, et al: Implication of endogenous prostaglandin system in the antihypertensive effect of captopril, SQ14225, in low renin hypertension. Jpn Circ J 44: 422, 1980.PubMedCrossRefGoogle Scholar
  36. 36.
    Swales JD: Arterial wall or plasma renin in hypertension. Clin Sci 56: 293, 1979.PubMedGoogle Scholar
  37. 37.
    Sullivan JM, Ginsburg BA, Ratts TE, et al: Haemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor. Hypertension 1: 397, 1979.PubMedGoogle Scholar
  38. 38.
    Swartz SL, Williams GH, Hollenberg NK, et al: Converting enzyme inhibition in essential hypertension: The hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1: 106, 1979.PubMedGoogle Scholar
  39. 39.
    Tree M, Morton JJ: Evidence that the acute hypotensive effect of captopril in dogs is not wholly explained by a reduction of plasma angiotensin II and its direct vasoconstrictor effect. Clin Sci 59: 451, 1980.PubMedGoogle Scholar
  40. 40.
    Moore TJ, Crantz FR, Hollenberg NK, et al: Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension 3: 168, 1981.PubMedGoogle Scholar
  41. 41.
    Sweet CS, Gross DM, Abergast PT, et al: Antihypertensive activity of N-(s)-1-(ethoxycarbonyl-3phenylpropyl)-L-ALA-L-PRO (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 216: 558, 1981.PubMedGoogle Scholar
  42. 42.
    Waeber B, Brunner HR, Brunner DB, et al: Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236, 1980.PubMedGoogle Scholar
  43. 43.
    Lijnen P, Fagard R, Staessen J, et al: Role of various vasodepressor systems in the acute hypotensive effect of captopril in man. Eur J Clin Pharmacol 20: 1, 1981.CrossRefGoogle Scholar
  44. 44.
    McCubbin JW, Demoura RS, Page IH, et al: Arterial hypertension elicited by sub-pressor amounts of angiotensin. Science 149: 1394, 1965.PubMedCrossRefGoogle Scholar
  45. 45.
    Bean BL, Brown JJ, Casals-Stenzel J, et al: Relation of arterial pressure and plasma angiotensin II concentration: A change produced by prolonged infusion of angiotensin II in the dog. Circ Res 44: 452, 1979.PubMedGoogle Scholar
  46. 46.
    Hall JE, Guyton AC, Smith MJ Jr, et al: Chronic blockade of angiotensin II formation during sodium deprivation. Am J Physiol 237: F424, 1979.PubMedGoogle Scholar
  47. 47.
    McCaa RE: Studies in vivo with angiotensin I converting enzyme (kininase II) inhibitors. Fed Proc 38: 2783, 1979.PubMedGoogle Scholar
  48. 48.
    Textor SC, Brunner HR, Gavras H: Converting enzyme inhibition during chronic angiotensin-II infusion in rats evidence against a non-angiotensin mechanism. Hypertension 3: 269, 1981.PubMedGoogle Scholar
  49. 49.
    Levens NR, Peach MJ, Vaughan ED Jr, et al: Responses of blood pressure and angiotensin converting enzyme activity to acute captopril administration in normotensive and hypertensive rats. Endocrinology 108: 536, 1981.PubMedCrossRefGoogle Scholar
  50. 50.
    Ferguson RK, Turini GA, Brunner HR, et al: A specific orally active inhibitor of angiotensin converting enzyme in man. Lancet 1: 775, 1977.CrossRefGoogle Scholar
  51. 51.
    Atkinson AB, Brown JJ, Fraser R, et al: Captopril in hypertension with renal artery stenosis and in intractable hypertension; acute and chronic changes in circulating concentrations of renin, angiotensin I and II and aldosterone, and in body composition. Clin Sci 57: 139s, 1979.Google Scholar
  52. 52.
    Thurston H, Swales JD, Bing RF, et al: Vascular renin-like activity and blood pressure maintenance in the rat. Studies of the effect of changes in sodium balance, hypertension and nephrectomy. Hypertension 1: 643, 1979.PubMedGoogle Scholar
  53. 53.
    Evered MD, Robinson MM, Richardson MA: Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain. Eur J Pharmacol 68: 443, 1980.PubMedCrossRefGoogle Scholar
  54. 54.
    Unger T, Kaufmann-Buhler I, Scholkens B, et al: Brain converting enzyme inhibition: a possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats. Eur J Pharmacol 70: 467, 1981.PubMedCrossRefGoogle Scholar
  55. 55.
    Crofton JT, Share L, Horovitz ZP: The effect of SQ14225 on systolic blood pressure and urinary excretion of vasopressin in the developing spontaneously hypertensive rat. Hypertension 1: 462, 1979.Google Scholar
  56. 56.
    Antonaccio MJ, Kerwin L: Evidence for prejunctional inhibition of norepinephrine release by captopril in spontaneously hypertensive rats. Eur J Pharmacol 68: 209, 1980.PubMedCrossRefGoogle Scholar
  57. 57.
    Maitra SR, Scicli AG, Miyazaki S, et al: Role of mineralocorticoid in the chronic antihypertensive effect of converting enzyme inhibitor. Hypertension 3: 205, 1981.PubMedGoogle Scholar
  58. 58.
    Zimmerman BG: Adrenergic facilitation by angiotensin: Does it serve a physiological function? Clin Sci 60: 343, 1981.PubMedGoogle Scholar
  59. 59.
    McCaa RE, Hall JE, McCaa CS: The effects of angiotensin I converting enzyme inhibitors on arterial blood pressure and urinary sodium excretion. Role of the renal reninangiotensin and kallikreinkinin system. Circ Res 43(Suppl 1):1–32, 1978.Google Scholar
  60. 60.
    Murthy VS, Waldron TL, Goldberg ME: Inhibition of angiotensin converting enzyme by SQ14,225 in anaesthetized dogs: Hemodynamic and renal vascular effects. Proc Soc Exp Biol Med 157: 121, 1978.PubMedGoogle Scholar
  61. 61.
    Clappison BH, Millar JA, Casley DJ, et al: Renal, adrenal and vascular changes during inhibition of converting enzyme with captopril. Clin Exp Pharmacol Physiol 7: 493, 1980.PubMedCrossRefGoogle Scholar
  62. 62.
    Meggs LG, Hollenberg NK: Converting enzyme inhibition and the kidney. Hypertension 2: 551, 1980.PubMedGoogle Scholar
  63. 63.
    Mimran A, Casellas D, Dupont M: Indirect evidence against a role of the kinin system in the renal haemodynamic effect of captopril in the rat. Kidney Int 18: 746, 1980.PubMedCrossRefGoogle Scholar
  64. 64.
    Zimmerman BG, Mommsen C, Kraft E: Renal vasodilatation caused by captopril in conscious normotensive and Goldblatt hypertensive dogs. Proc Soc Exp Biol Med 164: 459, 1980.PubMedGoogle Scholar
  65. 65.
    Nasjletti A, Colina-Chourio J, McGiff JC: Disappearance of bradykinin in renal circulation of dogs. Effects of kininase inhibition. Circ Res 37: 59, 1975.PubMedGoogle Scholar
  66. 66.
    Arendhorst WJ, Finn WF: Renal haemodynamics in the rat before and during inhibition of angiotensin II. Am J Physiol 223: F290, 1977.Google Scholar
  67. 67.
    Kimbrough HM Jr, Vaughan ED Jr, Carey RM, et al: Effect of intrarenal angiotensin II blockade on renal function in conscious dogs. Circ Res 40: 174, 1977.PubMedGoogle Scholar
  68. 68.
    Navar LG, Lagrange RA, Bell PD, et al: Glomerular and renal hemodynamics during converting enzyme inhibition (SQ20,881) in the dog. Hypertension 1: 371, 1979.PubMedGoogle Scholar
  69. 69.
    Johns EJ: Action of angiotensin I converting enzyme inhibitor on the control of renal function in the cat. Clin Sci 56: 365, 1979.PubMedGoogle Scholar
  70. 70.
    Abe Y, Katsuyuki M, Imanishi M, et al: Effects of an orally active converting enzyme inhibitor (YS-980) on renal function in dogs. J Pharmacol Exp Ther 214: 166, 1980.PubMedGoogle Scholar
  71. 71.
    Williams GH, Hollenberg NK: Accentuated vascular and endocrine response to SQ20881 in hypertension. N Engl J Med 297: 184, 1977.PubMedCrossRefGoogle Scholar
  72. 72.
    Freeman RH, Davis JO: Physiological actions of angiotensin II on the kidney. Fed Proc 38: 2276, 1979.PubMedGoogle Scholar
  73. 73.
    Funae Y, Komori T, Sasaki D, et al: Inhibitor of angiotensin I converting enzyme: (4R)-3-(2a)-3mercapto-2-methylpropanoyl-4-thiazolidinecarboxylic acid (YS-980). Biochem Pharmacol 29: 1543, 1980.PubMedCrossRefGoogle Scholar
  74. 74.
    Mullane KM: The formation and role of prostacyclin in the control of vascular tone. Ph.D. thesis, University of London, London, 1982.Google Scholar
  75. 75.
    Atlas SA, Case DB, Sealey JE, et al: Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1: 274, 1979.PubMedGoogle Scholar
  76. 76.
    Bengis RG, Coleman TG, Young DB, et al: Long-term blockade of angiotensin formation in various normotensive and hypertensive rat models using converting enzyme inhibitor (SQ14,225). Circ Res 43 (Suppl 1): 1–45, 1978.Google Scholar
  77. 77.
    MacGregor GA, Markanou ND, Roulston JE, et al: Essential hypertension: Effect of an oral inhibitor of angiotension-converting enzyme. Br Med J 2: 1106, 1979.PubMedCrossRefGoogle Scholar
  78. 78.
    White NJ, Yahayi H, Rajagopalan B: Captopril and frusemide in severe treatment-resistant hypertension. Lancet 2: 108, 1980.PubMedCrossRefGoogle Scholar
  79. 79.
    Sweet CS, Abergast P, Gaul SL, et al: Mechanisms involved in MK-421-induced hypotension in spontaneously hypertensive rats. Fed Proc 40: 487, 1981.Google Scholar
  80. 80.
    Vollmer RR, Boccagno JA, Harris DN, et al: Hypotension induced by inhibition of angiotensinconverting enzyme in pentobarbital-anaesthetized dogs. Eur J Pharmacol 51: 39, 1978.PubMedCrossRefGoogle Scholar
  81. 81.
    Hutchinson JS, Mendelsohn FAO, Doyle AE: Hypotensive action of captopril and saralasin in intact and anephric spontaneously hypertensive rats. Hypertension 2: 119, 1980.PubMedGoogle Scholar
  82. 82.
    Hutchinson JS, Mendelsohn FAO: Hypotensive effects of captopril administered centrally in intact conscious spontaneously hypertensive rats and peripherally in anephric anaesthetized spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 7: 555, 1980.PubMedCrossRefGoogle Scholar
  83. 83.
    Vandongen R, Tunney A, Martinez P: Effect of the converting enzyme inhibitor SQ14225 (captopril) in early one-kidney, one-clip hypertension in the rat. Clin Sci 60: 387, 1981.PubMedGoogle Scholar
  84. 84.
    Aguilera G, Schirar A, Baukal A, et al: Circulating angiotensin II and adrenal receptors after nephrectomy. Nature 289: 507, 1981.PubMedCrossRefGoogle Scholar
  85. 85.
    Hodge RL, Ng KKF, Vane JR: Disappearance of angiotensin from the circulation of the dog. Nature 215: 138, 1967.PubMedCrossRefGoogle Scholar
  86. 86.
    Carretero OA, Scicli AG: Possible role of kinins in circulatory homeostasis. State of the art review. Hypertension 3 (Suppl. 1 ): 1–4, 1981.Google Scholar
  87. 87.
    Mersey JH, Williams GH, Hollenberg NK, et al: Relationship between aldosterone and bradykinin. Circ Res 40 (Suppl 1 ): 1–84, 1977.Google Scholar
  88. 88.
    Crantz FR, Swartz SL, Hollenberg NK, et al: Differences in response to the peptidyldipeptide hydrolase inhibitors SQ20,881 and 5Q14,225 in normal renin essential hypertension. Hypertension 2: 604, 1980.PubMedGoogle Scholar
  89. 89.
    Swartz SL, Williams GH, Hollenberg NK, et al: Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man. J Clin Invest 65: 1257, 1980.PubMedCrossRefGoogle Scholar
  90. 90.
    Miller ED, Samuels AI, Haber E, et al: Inhibition of angiotensin conversion and prevention of renal hypertension. Am J Physiol 228: 448, 1975.PubMedGoogle Scholar
  91. 91.
    Haber E, Sanco J, Re J, et al: The role of the renin—angiotensin—aldosterone system in cardiovascular homeostasis in normal man. Clin Sci Mol Med 48 (Suppl 2): 49, 1975.Google Scholar
  92. 92.
    Johnston CI, Millar JA, McGrath BP, et al: Long-term effects of captopril (SQ14225) on blood-pressure and hormone levels in essential hypertension. Lancet 2: 493, 1979.PubMedCrossRefGoogle Scholar
  93. 93.
    Vinci JM, Horwitz D, Zusman RM, et al: The effect of converting enzyme inhibition with SQ20881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension 1: 416, 1979.PubMedGoogle Scholar
  94. 94.
    Matthews PG, Johnston CI: Changes in endogenous circulating angiotensin and bradykinin after inhibition of converting enzyme (kininase II). Med J Aust 2: 12, 1979.Google Scholar
  95. 95.
    Hulthen L, Hokfelt B: The effect of the converting enzyme inhibitor SQ 20,881 on kinins, renin—angiotensin—aldosterone and catecholamines in relation to blood pressure in hypertensive patients. Acta Med Scand 204: 497, 1978.PubMedCrossRefGoogle Scholar
  96. 96.
    Carretero OA, Scicli AG: The renal kallikrein—kinin system. Am J Physiol 238: F247, 1980.PubMedGoogle Scholar
  97. 97.
    Olsen UB, Arrigoni-Martelli E: The effects of kininase II inhibition by SQ14225 on kidney kallikrein—kinin and prostaglandin systems in conscious dogs. Eur J Pharmacol 54: 229, 1979.PubMedCrossRefGoogle Scholar
  98. 98.
    Regoli D, Barabe J: Pharmacology of bradykinin and related kinins Pharm Rev 32: 1, 1980.PubMedGoogle Scholar
  99. 99.
    Haberland G, McConn R: A rationale for the therapeutic action of aprotinin. Fed Proc 38: 2760, 1979.PubMedGoogle Scholar
  100. 100.
    Mimran A, Targhetta R, Laroche B: The antihypertensive effect of captopril. Evidence for an influence of kinins. Hypertension 2: 732, 1980.PubMedGoogle Scholar
  101. 101.
    Overlack A, Stumpe KO, Kuhnert M, et al: Altered blood pressure and renin responses to converting enzyme inhibition after aprotinin-induced kallikrein-kinin-system blockade. Clin Sci 59: 129s, 1980.Google Scholar
  102. 102.
    Carretero OA, Oza NB, Piwonska A, et al: Measurement of urinary kallikrein activity by kinin radioimmunoassay. Biochem Pharmacol 25: 2265, 1976.PubMedCrossRefGoogle Scholar
  103. 103.
    Carretero OA, Miyazaki S, Scicli AG: Role of kinins in the acute antihypertensive effect of the enzyme inhibitor, captopril. Hypertension 3: 18, 1981.PubMedGoogle Scholar
  104. 104.
    Miyazaki S, Scicli AG, Polomski C, et al: Role of kinins in the antihypertensive effects of converting enzyme inhibitor. Circulation 60 (Suppl 1): 228, 1979.Google Scholar
  105. 105.
    Piper PJ, Vane JR: Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 223: 29, 1969.PubMedCrossRefGoogle Scholar
  106. 106.
    McGiff JC, Terragno NA, Malik KU, et al: Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 31: 36, 1972.PubMedGoogle Scholar
  107. 107.
    Vane JR, Ferreira SH: Interactions between bradykinin and prostaglandins, in Pisano JJ, Austen KF (eds): Chemistry and Biology of the Kallikrein—Kinin System in Health and Disease. Fogarty International Center Proceedings No. 27, US Government Printing Office, Washington, 1976.Google Scholar
  108. 108.
    Blumberg AL, Denny SE, Marshall GR, et al: Blood vessel—hormone interactions: angiotensin, bradykinin, and prostaglandins. Am J Physiol 232: H305, 1977.PubMedGoogle Scholar
  109. 109.
    Terragno NA, Lonigro AJ, Malik KU, et al: The relationship of the renal vasodilator action of bradykinin to the release of a prostaglandin E-like substance. Experientia 28: 437, 1972.PubMedCrossRefGoogle Scholar
  110. 110.
    Nasjletti A, McGiff JC, Colina-Chourio J: Interrelations of the renal kallikrein-kinin system and renal prostaglandins in the conscious rat. Influence of mineralocorticoids. Circ Res 43: 799, 1978.PubMedGoogle Scholar
  111. 111.
    Mullane KM, Moncada S: Prostacyclin release and the modulation of some vasoactive hormones. Prostaglandins 20: 25, 1980.PubMedCrossRefGoogle Scholar
  112. 112.
    McGiff JC, Crowshaw K, Terragno NA, et al: Release of a prostaglandin-like substance into renal venous blood in response to angiotensin II. Circ Res 26 (Suppl 1): 121, 1970.Google Scholar
  113. 113.
    Aiken JW, Vane JR: Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 184: 678, 1973.PubMedGoogle Scholar
  114. 114.
    Kalisker A, Dyer DC: In vitro release of prostaglandins from the renal medulla. Eur J Pharmacol 19: 305, 1972.PubMedCrossRefGoogle Scholar
  115. 115.
    Walker LA, Whorton AR, Smigel M, et al: Antidiuretic hormone increases renal prostaglandin synthesis in vivo. Am J Physiol 235: F180, 1978.Google Scholar
  116. 116.
    Mullane KM, Moncada S: Prostacyclin mediates the potentiated hypotensive effect of bradykinin following captopril treatment. Eur J Pharmacol 66: 355, 1980.PubMedCrossRefGoogle Scholar
  117. 117.
    Murthy VS, Waldron TL, Goldberg ME: The mechanisms of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ14,225 in conscious rabbits. Circ Res 43 (Suppl 1 ): 1–40, 1978.Google Scholar
  118. 118.
    Mullane KM, Moncada S, Vane JR: Prostacyclin release induced by bradykinin may contribute to the antihypertensive action of angiotensin-converting enzyme inhibitors, in Samuelsson B, Ramwell PW, Paoletti R (eds): Advances in Prostaglandin and Thromboxane Research. New York, Raven Press, vol 7, 1980, pp 1159–1161.Google Scholar
  119. 119.
    Johns EJ: Action of angiotensin I converting enzyme inhibitor on the control of renal function in the cat. Clin Sci 56: 365, 1979.PubMedGoogle Scholar
  120. 120.
    Wong PC, Zimmerman BG: Mechanism of captopril-induced renal vasodilatation in anesthetized dogs after nonhypotensive hemorrhage. J Pharmacol Exp Ther 215: 104, 1980.PubMedGoogle Scholar
  121. 121.
    Barr JG, Diz D, Kauker ML et al: Effect of the converting enzyme inhibitor SQ20881 on urinary excretion of prostaglandin E2 in the rat: Influence of pretreatment with deoxycorticosterone. J Pharmacol Exp Ther 215: 172, 1980.PubMedGoogle Scholar
  122. 122.
    Provoost AP: The effect of prostaglandin synthesis inhibition on the acute blood pressure reduction by captopril in pentobarbital-anaesthized rats. Eur J Pharmacol 65: 425, 1980.PubMedCrossRefGoogle Scholar
  123. 123.
    Dollery CT, Miyamori I: Indomethacin and the hypotensive action of captopril in DOCA salt hypertensive rats. Br J Pharmacol 68: 117P, 1980.Google Scholar
  124. 124.
    Cushman DW, Ondetti MA: Inhibitors of angiotensin-converting enzyme for treatment of hypertension. Biochem Pharm 29: 1871, 1980.PubMedCrossRefGoogle Scholar
  125. 125.
    Quilley CP, Chiba S, Quilley J, et al: Captopril enhances prostaglandin synthesis in SHR rats but aspirin potentiates its antihypertensive actions. Fed Proc 40: 681, 1981.Google Scholar
  126. 126.
    DiNicolantonio R, Dusting GJ, Hutchinson JS, et al: Failure of aspirin to modify the hypotensive action of captopril in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 8: 345, 1981.PubMedCrossRefGoogle Scholar
  127. 127.
    Antonaccio MJ, Harris D, Goldenberg H, et al: The effects of captopril, propranolol, and indomethacin on blood pressure and plasma renin activity in spontaneously hypertensive and normotensive rats. Proc Soc Exp Biol Med 162: 429, 1979.PubMedGoogle Scholar
  128. 128.
    Malik KU, McGiffJC: Modulation by prostaglandins of adrenergic transmission in the isolated perfused rabbit and rat kidney. Circ Res 36: 599, 1975.PubMedGoogle Scholar
  129. 129.
    Armstrong JM, Blackwell GJ, Flower RJ, et al: Genetic hypertension in rats is accompanied by a defect in renal prostaglandin catabolism. Nature 260: 582, 1976.PubMedCrossRefGoogle Scholar
  130. 130.
    Baer PG, McGiff JC: Comparison of effects of prostaglandins E2 and I2 on rat renal vascular resistance. Eur J Pharmacol 54: 359, 1979.PubMedCrossRefGoogle Scholar
  131. 131.
    Gerber JG, Nies AS: The hemodynamic effects of prostaglandins in the rat. Evidence for important species variation in renovascular responses. Circ Res 44: 406, 1979.PubMedGoogle Scholar
  132. 132.
    Vio CP, Guivernau M, Terragno A, et al: Effect of captopril on the biosynthesis of prostaglandins in vitro. Fed Proc 40: 702, 1981.Google Scholar
  133. 133.
    Gerber JG, Branch RA, Nies AS, et al: Prostaglandins and renin release: II. Assessment of renin secretion following infusion of PGI2, E2 and D2 into the renal artery of anaesthetized dogs. Prostaglandins 15: 81, 1978.PubMedCrossRefGoogle Scholar
  134. 134.
    Whorton AR, Misono K, Hollifield J, et al.: Prostaglandins and renin release: I. Stimulation of renin release from rabbit renal cortical slices by PGI2. Prostaglandins 14: 1095, 1977.PubMedCrossRefGoogle Scholar
  135. 135.
    Abe K, Itoh T, Sato M, et al: Indomethacin (IND) inhibits an enhanced renin release following the captopril, SQ14225, administration. Life Sci 26: 561, 1980.PubMedCrossRefGoogle Scholar
  136. 136.
    Laffan RJ, Goldberg ME, High JP, et al: Antihypertensive activity in rats of SQ14,225, an orally active inhibitor of angiotensin I-converting enzyme. J Pharmacol Exp Ther 204: 281, 1978.PubMedGoogle Scholar
  137. 137.
    Muirhead EE, Prewitt RL Jr, Brooks B, et al: Antihypertensive action of the orally active converting enzyme inhibitor (SQ14,225) in spontaneously hypertensive rats. Circ Res 43 (Suppl 1): 1–53, 1978.Google Scholar
  138. 138.
    Harris DN, Heran CL, Goldenberg HJ, et al: Effects of SQ14,225, an orally active inhibitor of angiotensin-converting enzyme on blood pressure, heart rate and plasma renin activity of conscious normotensive dogs. Eur J Pharmacol 51: 345, 1978.PubMedCrossRefGoogle Scholar
  139. 139.
    Rubin B, Laffan RJ, Kotler D, et al: SQ14,225 (D-3-mercapto-2-methylpropanoyl-L-proline), a novel orally active inhibitor of angiotensin-I-converting enzyme. J Pharmacol Exp Ther 204: 271, 1978.PubMedGoogle Scholar
  140. 140.
    Jandhyala BS, Nandiwada P, Buckley JP, et al: Studies on the mechanism of the hypotensive action of 5Q14,225, an angiotensin-converting enzyme inhibitor in anesthetized dogs. Res Commun Chem Pathol Pharmacol 25: 429, 1979.PubMedGoogle Scholar
  141. 141.
    Phelan EL, Clark DWJ: Effect of captopril on blood pressure and vascular resistance in normotensive and genetically hypertensive rats. Med J Aust 2: 16, 1979.Google Scholar
  142. 142.
    Okuno T, Kondo K, Konishi K, et al: SQ14,225 attenuates the vascular response to norepinephrine in the rat mesenteric arteries. Life Sci 25: 1343, 1979.PubMedCrossRefGoogle Scholar
  143. 143.
    Chiba S, Quilley CP, Quilley J, et al: Effect of captopril on norepinephrine-induced vasoconstriction and prostaglandin release in the rat kidney. Fed Proc 40: 703, 1981.Google Scholar
  144. 144.
    Ljung B, Jandhyala B, Kjellstedt A: Angiotensin I converting enzyme activity in portal vein studied in normotensive rats and in models of primary and secondary hypertension. Acta Physiol Scand 111: 409, 1981.PubMedCrossRefGoogle Scholar
  145. 145.
    Ito K, Koike H, Miyamoto M, Urakawa N: Long-term blockade of angiotension-converting enzyme alters passive ion transport of vascular smooth muscle. Life Sci 26: 1023, 1980.PubMedCrossRefGoogle Scholar
  146. 146.
    Clough DP, Hatton R, Matthewman SC: Effect of an angiotensin converting enzyme inhibitor on neurogenic vasoconstriction in the pithed rat. Br J Pharmacol 73: 296P, 1981.Google Scholar

Copyright information

© Plenum Publishing Corporation 1983

Authors and Affiliations

  • Kevin Mullane
    • 1
  • Salvador Moncada
    • 1
  • John R. Vane
    • 1
  1. 1.Wellcome Research LaboratoriesBeckenham, KentEngland

Personalised recommendations